<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870569</url>
  </required_header>
  <id_info>
    <org_study_id>RG01N-1271</org_study_id>
    <nct_id>NCT02870569</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donafenib for advanced 131I-refractory/resistant differentiated thyroid cancer(DTC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess efficacy and safety in patients with
      131I-refractory/resistant differentiated thyroid cancer.The study is a
      randomised,multicentre,open-label study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>ORR is defined as the percentage of subjects with total number of Complete Response(CR)+total number of Partial Response(PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 48 months treatment</time_frame>
    <description>OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>PFS was defined as the time from date of randomization to disease progression radiological or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables will be summarized using descriptive statistics based on adverse events collection</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>Patients with adverse events/all patients *100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 24 months treatment</time_frame>
    <description>DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Differentiated Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Donafenib1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the lower dose group. Donafenib 200mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donafenib2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the higher dose group. Donafenib 300mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib 200mg</intervention_name>
    <description>Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.</description>
    <arm_group_label>Donafenib1</arm_group_label>
    <other_name>lower dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donafenib 300mg</intervention_name>
    <description>Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.</description>
    <arm_group_label>Donafenib2</arm_group_label>
    <other_name>higher dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastases thyroid cancer;

          -  Subjects must have histologically or cytologically confirmed diagnosis of one of the
             following differentiated thyroid cancer (DTC) subtypes: papillary thyroid cancer
             (PTC),follicular thyroid cancer (FTC) or Hurthle cell ;

          -  Measurable disease meeting the following criteria and confirmed by central
             radiographic review:

               1. At least 1 lesion of greater than or equal to 1.0 cm in the longest diameter for
                  a non-lymph node or greater than or equal to 1.5 cm in the short-axis diameter
                  for a lymph node which is serially measurable according to RECIST 1.1 using
                  computerized tomography.

               2. Lesions that have had external beam radiotherapy (EBRT) or loco-regional
                  therapies such as radio-frequency (RF) ablation must show evidence of progressive
                  disease based on RECIST 1.1 to be deemed a target lesion;

               3. Bone metastases lesion is non-measurable.

          -  Subjects must show evidence of disease progression within 14 months prior to signing
             informed consent, according to RECIST 1.1 assessed and confirmed by central
             radio-graphic review of CT scans.

          -  Subjects must be 131I-refractory / resistant as defined by at least one of the
             following:

               1. One or more measurable lesions that do not demonstrate iodine uptake on any
                  radio-iodine scan

               2. One or more measurable lesions that has progressed by RECIST 1.1 within 14 months
                  of 131I therapy, despite demonstration of radio-iodine avidity at the time of
                  that treatment by pre-treatment scanning.

               3. Cumulative activity of 131I of &gt;600 mCi or 22 gigabequerels (GBq), with the last
                  dose administered at least 6 months prior to study entry

          -  Subjects may have not received molecular targeted therapy;

          -  Subjects with known brain metastases who have completed whole brain radiotherapy,
             stereotactic radiosurgery or complete surgical resection, will be eligible if they
             have remained clinically stable, asymptomatic and off of steroids for one month

          -  Subjects must tolerate to thyroxin ,and TSH suppression (TSH less than 0.1 mU/mL);

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
             0~2；

          -  Life expectancy of at least 3 months;

          -  Adequate bone marrow function:

               1. Absolute neutrophil count (ANC) greater than or equal to 1500/mm3;

               2. Platelets greater than or equal to 100,000/mm3 ;

               3. Hemoglobin greater than or equal to 9.0g/dL

          -  Adequate blood coagulation function:

               1. Prothrombin time(PT)≤17s;

               2. Activated prothrombin time(APTT)≤47s;

               3. International Normalized Ratio(INR)≤2.

          -  Adequate liver function:

               1. Bilirubin less than or equal to 1.5 x the upper limit of normal(ULN) ;

               2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
                  aminotransferase (AST) less than or equal to 2.5 x the upper limit of normal
                  (ULN).

          -  All females must have a negative serum or urine pregnancy test. Females of
             childbearing potential and male subjects who are partners of women of childbearing
             potential must use or their partners must use a highly effective method of
             contraception;

          -  Voluntary provision of written informed consent and the willingness and ability to
             comply with all aspects of the protocol.

        Exclusion Criteria:

          -  Anaplastic or Medullary carcinoma of the thyroid;

          -  Prior treatment to sorafenib or other molecular targeted drugs;

          -  Subjects who have received any chemotherapy or extra radiotherapy within 30 days prior
             to the first dose of study drug and should have recovered from any toxicity related to
             previous anti-cancer treatment;

          -  Major surgery within 30 days prior to the first dose of study drug;

          -  Significant cardiovascular impairment: history of congestive heart failure greater
             than New York Heart Association (NYHA) Class II, unstable angina; myocardial
             infarction or stroke within 6 months of the first dose of study drug, or cardiac
             arrhythmia requiring medical treatment;

          -  Active infection (any infection requiring treatment);

          -  Active malignancy (except for differentiated thyroid carcinoma, or definitively
             treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma
             in-situ of the cervix) within the past 24 months;

          -  Known intolerance to any of the study drugs (or any of the excipients);

          -  All chemotherapy or radiation-related toxicities must have resolved to less than Grade
             2 severity, except alopecia and infertility;

          -  Adequately controlled blood pressure with or without antihypertensive medications,
             defined as BP less than 140/90 mmHg using at least 2 kinds of medicine;

          -  Adequate renal function defined as calculated creatinine clearance less than or equal
             to 60 mL/min per the Cockcroft and Gault formula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yan Song, MD</last_name>
    <phone>13671116837</phone>
    <email>linys@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lin Yan Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

